Plain-English translation of NCT07030283 on ClinicalTrials.gov ↗ ·
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new combination treatment for pancreatic cancer that has spread to the lining of the abdomen. You would receive (a chemotherapy drug) injected directly into your abdomen, combined with , a four-drug chemotherapy combination given through a vein. The goal is to see whether this combination is safe and whether it works better than standard treatment alone.
Pancreatic cancer that spreads to the abdomen is very difficult to treat and has a poor prognosis. Researchers hope that delivering one chemotherapy drug directly to where the cancer has spread, combined with standard systemic chemotherapy, may be more effective and help more patients become candidates for surgery.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic every two weeks for treatment cycles lasting 14 days. On days 1 and 8 of each cycle, you would receive the medication injected into your abdominal port; on day 1, you would also receive the intravenous chemotherapy through a vein. Treatment may continue for up to 12 cycles (about 6 months). At each visit, you would have blood work, imaging scans, and abdominal fluid testing to monitor how the cancer responds, and you would complete questionnaires about how the treatment affects you. If the cancer responds well, you may become eligible for surgery, and you would continue follow-up visits to monitor your health over time.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States